Education
About Us
Working with TipRanks
Follow Us
Cel-Sci Corp. (CVM)
XASE:CVM
CVM Stock Chart & Stats
$5.19
-$0.03(-7.92%)
At close: 4:00 PM EST
$5.19
-$0.03(-7.92%)
Day’s Range― - ―
52-Week Range$1.98 - $13.48
Previous Close$0.36
Volume1.47M
Average Volume (3M)125.69K
Market Cap
$29.10M
Enterprise Value$27.99M
Total Cash (Recent Filing)$6.28M
Total Debt (Recent Filing)$10.63M
Price to Earnings (P/E)―
Beta1.56
Next Earnings
May 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.68
Shares Outstanding8,457,967
10 Day Avg. Volume66,836
30 Day Avg. Volume125,686
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.34
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-7.26
Enterprise Value/Ebitda-1.44
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-4.16
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Clinical-stage Lead Program (Multikine)CEL-SCI's corporate strategy centers on one lead immunotherapy, Multikine, which concentrates R&D resources and regulatory effort. A single, clearly defined clinical program reduces dispersion of capital and management attention, improving execution odds and long-term commercialization focus if trials succeed.
Narrowing Net Losses Over Multi-year TrendProgressive reduction in net losses across multiple years signals sustained expense control and operational discipline. For a pre-revenue biotech, shrinking losses extend runway and lower incremental financing needs, making continued clinical development more sustainable over the coming months.
Consistent, Predictable Operating Cash BurnStable TTM operating cash outflows near -$17M suggest a predictable cash-burn profile rather than wildly fluctuating spending. Predictability in burn allows management to plan financings and trial milestones more effectively, reducing execution risk tied to unexpected expense spikes.
Bears Say
No Reported Revenue; Pre-revenue ProfileThe company remains pre-revenue and fully dependent on clinical success and external financing. Absent commercial sales, long-term viability hinges on trial outcomes and capital markets access, raising structural funding and dilution risk until commercialization is achieved.
Extremely Volatile/outlier Balance Sheet MetricsAnomalous 2025 balance-sheet reading with massive reported debt and extreme leverage creates significant financing and credibility risk. Even if a data outlier, such volatility undermines confidence in solvency metrics and complicates long-term planning and lender/investor assessment.
Persistent Negative Cash Flow And Funding RelianceSustained negative operating and free cash flow indicates the business consumes cash without internal generation. With free cash flow closely tracking losses, there is limited non-cash offset, meaning ongoing external funding is required to sustain trials and operations, elevating dilution and execution risk.
Cel-Sci News
CVM FAQ
What was Cel-Sci Corp.’s price range in the past 12 months?
Cel-Sci Corp. lowest stock price was $1.98 and its highest was $13.48 in the past 12 months.
What is Cel-Sci Corp.’s market cap?
Cel-Sci Corp.’s market cap is $29.10M.
When is Cel-Sci Corp.’s upcoming earnings report date?
Cel-Sci Corp.’s upcoming earnings report date is May 14, 2026 which is in 51 days.
How were Cel-Sci Corp.’s earnings last quarter?
Cel-Sci Corp. released its earnings results on Feb 18, 2026. The company reported -$0.68 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.68.
Is Cel-Sci Corp. overvalued?
According to Wall Street analysts Cel-Sci Corp.’s price is currently Overvalued.
Does Cel-Sci Corp. pay dividends?
Cel-Sci Corp. does not currently pay dividends.
What is Cel-Sci Corp.’s EPS estimate?
Cel-Sci Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cel-Sci Corp. have?
Cel-Sci Corp. has 8,457,967 shares outstanding.
What happened to Cel-Sci Corp.’s price movement after its last earnings report?
Cel-Sci Corp. reported an EPS of -$0.68 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 8.368%.
Which hedge fund is a major shareholder of Cel-Sci Corp.?
Currently, no hedge funds are holding shares in CVM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cel-Sci Corp.
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
Technical Analysis
Ownership Overview
2.51% Insiders
3.60% Mutual Funds
0.09% Other Institutional Investors
91.04% Public Companies and
Individual Investors